166 related articles for article (PubMed ID: 23171462)
1. The role of AHI1 and CDKN1C in cutaneous T-cell lymphoma progression.
Litvinov IV; Kupper TS; Sasseville D
Exp Dermatol; 2012 Dec; 21(12):964-6. PubMed ID: 23171462
[TBL] [Abstract][Full Text] [Related]
2. Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma.
Huang Y; Su MW; Jiang X; Zhou Y
Blood; 2015 Feb; 125(9):1435-43. PubMed ID: 25548321
[TBL] [Abstract][Full Text] [Related]
3. Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells.
Kennah E; Ringrose A; Zhou LL; Esmailzadeh S; Qian H; Su MW; Zhou Y; Jiang X
Blood; 2009 May; 113(19):4646-55. PubMed ID: 19211505
[TBL] [Abstract][Full Text] [Related]
4. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
[TBL] [Abstract][Full Text] [Related]
5. CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma.
Laharanne E; Chevret E; Idrissi Y; Gentil C; Longy M; Ferrer J; Dubus P; Jouary T; Vergier B; Beylot-Barry M; Merlio JP
Mod Pathol; 2010 Apr; 23(4):547-58. PubMed ID: 20118908
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma.
Litvinov IV; Jones DA; Sasseville D; Kupper TS
Clin Cancer Res; 2010 Apr; 16(7):2106-14. PubMed ID: 20233883
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
9. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
[TBL] [Abstract][Full Text] [Related]
10. The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL).
Litvinov IV; Netchiporouk E; Cordeiro B; Doré MA; Moreau L; Pehr K; Gilbert M; Zhou Y; Sasseville D; Kupper TS
Clin Cancer Res; 2015 Jun; 21(12):2820-9. PubMed ID: 25779945
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional Heterogeneity and the Microbiome of Cutaneous T-Cell Lymphoma.
Licht P; Mailänder V
Cells; 2022 Jan; 11(3):. PubMed ID: 35159138
[TBL] [Abstract][Full Text] [Related]
13. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
[TBL] [Abstract][Full Text] [Related]
14. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN.
Scarisbrick JJ; Woolford AJ; Russell-Jones R; Whittaker SJ
Blood; 2000 May; 95(9):2937-42. PubMed ID: 10779442
[TBL] [Abstract][Full Text] [Related]
16. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
17. Early changes in gene expression of the entire pathological process in Cutaneous T-cell lymphoma.
Li Y; Wang X; Li Y; Ma R; Zhao Z; Ren J; Men J
J Cell Biochem; 2019 Oct; 120(10):17472-17480. PubMed ID: 31106473
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.
van Doorn R; Zoutman WH; Dijkman R; de Menezes RX; Commandeur S; Mulder AA; van der Velden PA; Vermeer MH; Willemze R; Yan PS; Huang TH; Tensen CP
J Clin Oncol; 2005 Jun; 23(17):3886-96. PubMed ID: 15897551
[TBL] [Abstract][Full Text] [Related]
19. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
[TBL] [Abstract][Full Text] [Related]
20. Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis.
Miyagaki T; Sugaya M; Suga H; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e60-7. PubMed ID: 22404649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
